Keywords for this news article include: Chongqing, People's Republic of China, Asia, Antiparkinson Agents, Basal Ganglia Diseases and Conditions, Brain Diseases and Conditions, Central Nervous System Agents, Central Nervous System Diseases and Conditions, Dihydroxyphenylalanine, Dopaminergic Antiparkinsonism Agents, Drugs and Therapies, Dyskinesias, Health and Medicine, Levodopa, Levodopa Therapy, Movement Disorders, Musculoskeletal Diseases and Conditions, Nervous System Diseases and Conditions, Neurodegenerative Diseases and Conditions, Neurologic Manifestations, Neurology, Parkinson's Disease, Parkinsonian Disorders, Pharmaceuticals, Chongqing Medical University. Chongqing, People's Republic of China, Asia, Antiparkinson Agents, Basal Ganglia Diseases and Conditions, Brain Diseases and Conditions, Central Nervous System Agents, Central Nervous System Diseases and Conditions, Dopaminergic Antiparkinsonism Agents, Drugs and Therapies, Dyskinesias, Health and Medicine, Levodopa, Levodopa Therapy, Movement Disorders, Musculoskeletal Diseases and Conditions, Nervous System Diseases and Conditions, Neurodegenerative Diseases and Conditions, Neurologic Manifestations, Neurology, Parkinson's Disease, Parkinsonian Disorders, Pharmaceuticals, Dihydroxyphenylalanine. [Extracted from the article]